Company Overview
| Stock Name | Carsgen-B |
|---|---|
| Stock Code | 02171 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們是一家在中國及美國擁有業務的生物製藥公司,專注於治療血液惡性腫瘤和實體瘤的創新CAR-T細胞療法。 |
| Listing Date | 2021-06-18 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 上海市徐匯區銀都路388號12幢 |
| Business Address (Hong Kong) | 香港 皇后大道東183號 合和中心54樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | carsgen.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 32.80 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 500 shares |
| Entry Threshold | HK$ 16,400 |
| Par Value | To be extracted |
| Offer Period | 2021-06-07 to 2021-06-10 |
| Global Offering Shares | 94,747,000 shares |
| HK Public Offer Shares (Initial) | 9,475,000 shares (10.0%) |
| Public Offer Lots (Initial) | 18,950lots (Pool A9,475lots,Pool B9,475lots) |
| International Placing Shares (Initial) | 85,272,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 567,346,696 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 49.9% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 3,107,701,600 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 500 | HK$ 16,400 |
| 2 lots | 1,000 | HK$ 32,800 |
| 3 lots | 1,500 | HK$ 49,200 |
| 4 lots | 2,000 | HK$ 65,600 |
| 5 lots | 2,500 | HK$ 82,000 |
| 6 lots | 3,000 | HK$ 98,400 |
| 7 lots | 3,500 | HK$ 114,800 |
| 8 lots | 4,000 | HK$ 131,200 |
| 9 lots | 4,500 | HK$ 147,600 |
| 10 lots | 5,000 | HK$ 164,000 |
| 12 lots | 6,000 | HK$ 196,800 |
| 14 lots | 7,000 | HK$ 229,600 |
| 16 lots | 8,000 | HK$ 262,400 |
| 18 lots | 9,000 | HK$ 295,200 |
| 20 lots | 10,000 | HK$ 328,000 |
| 30 lots | 15,000 | HK$ 492,000 |
| 40 lots | 20,000 | HK$ 656,000 |
| 50 lots | 25,000 | HK$ 820,000 |
| 60 lots | 30,000 | HK$ 984,000 |
| 70 lots | 35,000 | HK$ 1,148,000 |
| 80 lots | 40,000 | HK$ 1,312,000 |
| 90 lots | 45,000 | HK$ 1,476,000 |
| 100 lots | 50,000 | HK$ 1,640,000 |
| 120 lots | 60,000 | HK$ 1,968,000 |
| 140 lots | 70,000 | HK$ 2,296,000 |
| 160 lots | 80,000 | HK$ 2,624,000 |
| 180 lots | 90,000 | HK$ 2,952,000 |
| 200 lots | 100,000 | HK$ 3,280,000 |
| 300 lots | 150,000 | HK$ 4,920,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 400 lots | 200,000 | HK$ 6,560,000 |
| 500 lots | 250,000 | HK$ 8,200,000 |
| 600 lots | 300,000 | HK$ 9,840,000 |
| 700 lots | 350,000 | HK$ 11,480,000 |
| 800 lots | 400,000 | HK$ 13,120,000 |
| 900 lots | 450,000 | HK$ 14,760,000 |
| 1,000 lots | 500,000 | HK$ 16,400,000 |
| 1,200 lots | 600,000 | HK$ 19,680,000 |
| 1,400 lots | 700,000 | HK$ 22,960,000 |
| 1,600 lots | 800,000 | HK$ 26,240,000 |
| 1,800 lots | 900,000 | HK$ 29,520,000 |
| 2,000 lots | 1,000,000 | HK$ 32,800,000 |
| 3,000 lots | 1,500,000 | HK$ 49,200,000 |
| 4,000 lots | 2,000,000 | HK$ 65,600,000 |
| 5,000 lots | 2,500,000 | HK$ 82,000,000 |
| 6,000 lots | 3,000,000 | HK$ 98,400,000 |
| 7,000 lots | 3,500,000 | HK$ 114,800,000 |
| 8,000 lots | 4,000,000 | HK$ 131,200,000 |
| 9,475 lots | 4,737,500 | HK$ 155,390,000 |
Stock Connect Inclusion Analysis
| Avg Daily HK Mkt Cap | HK$ 8.69B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 18,608,971,628 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不適用(公司處於虧損狀態) |
| Profit/Loss Status | 虧損人民幣1,064.0百萬元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Balance Sheet
| Item | 2019 | 2020 |
|---|---|---|
| Cash and cash equivalents | 568,672 | 667,789 |
| Total current assets | 662,717 | 761,760 |
| Total assets | 772,856 | 877,710 |
| Total current liabilities | 781,649 | 887,699 |
| Total liabilities | 820,756 | 927,788 |
| Total equity | -470,768 | -550,078 |
| Equity attributable to owners | -570,659 | -549,087 |
Cash Flow Statement
| Item | 2019 | 2020 |
|---|---|---|
| Net cash from operating activities | -560,762 | -665,083 |
| Net cash from investing activities | 552,661 | -677,082 |
| Net cash from financing activities | 670,771 | 765,081 |
| Net increase in cash | 559,680 | 566,074 |
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 30.0 |
|---|---|
| First Day Open | HK$ 27.05 |
| First Day Change | -8.54% |
| First Day Volume | 54398500.0 |
| First Day Turnover | 1608210000.0 |
| Use of Proceeds | 1、約882.1百萬港元(113.7百萬美元)(或約30%的所得款項凈額)將用于為進一步開發我們的核心候選產品BCMA CAR-T (CT053)提供資金;
2、約911.6百萬港元(117.5百萬美元)(或約31%的所得款項凈額)將用于為我們正在進行及已籌劃的其他管線候選產品的研發活動提供資金;
3、約588.2百萬港元(75.8百萬美元)(或約20%的所得款項凈額)用于培養全面的制造及商業化能力;
4、約147.0百萬港元(37.9百萬美元)(或約10%的所得款項凈額)用于繼續升級CAR-T技術及為早期研發活動提供資金;
5、約264.7百萬港元(34.1百萬美元)(或約9%的所得款項凈額)將用于營運資金及其他一般公司用途。 |
Underwriting Syndicate
Overall Coordinators (4)
Joint Bookrunners (4)
Joint Lead Managers (4)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | CloudAlpha Master Fund | 235,930,400 HKD | — | 7.59% | — | 6 months | 2021-12-18 |
| 2 | Dymon Asia Capital (Singapore) Pte. Ltd. | 67,518,800 HKD | — | 2.17% | — | 6 months | 2021-12-18 |
| 3 | Foresight Orient Global Superior Choice SPC | 202,556,400 HKD | — | 6.52% | — | 6 months | 2021-12-18 |
| 4 | LAV Amber Limited | 337,594,000 HKD | — | 10.86% | — | 6 months | 2021-12-18 |
| 5 | WT Asset Management Limited | 135,037,600 HKD | — | 4.35% | — | 6 months | 2021-12-18 |
| 6 | 常春藤资产管理(香港)有限公司 | 67,518,800 HKD | — | 2.17% | — | 6 months | 2021-12-18 |
| 7 | 广发基金管理有限公司 | 135,037,600 HKD | — | 4.35% | — | 6 months | 2021-12-18 |
| 8 | 南方基金管理股份有限公司 | 67,518,800 HKD | — | 2.17% | — | 6 months | 2021-12-18 |
| 9 | 新华资本管理有限公司 | 303,449,200 HKD | — | 9.76% | — | 6 months | 2021-12-18 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 李宗海 | — |
| Company Secretary | 呂穎一 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 李博士、郭炳森先生、王博士、郭華清先生等一致行動方,緊隨全球發售完成後合共持有約37.92%股權。 |
|---|




